Rami A. Jahmani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rami A. Jahmani has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ali Ahmad Al-Omari
Department of Special Surgery, Division of Orthopedic Surgery, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan
1 shared publication - Belal Alsinglawi
Western Sydney University
1 shared publication Dawood Yusef
Department of Pediatrics and Neonatology, Jordan University of Science and Technology, Irbid, Jordan
1 shared publication- Faisal Nimri
Internal Medicine, Henry Ford Health System, Detroit, USA
1 shared publication - Ismail I. Matalka
Department of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan
1 shared publication - Khaldoon Alawneh
Department of Internal Medicine, Division of Rheumatology, School of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan
1 shared publication
Latest Publications
- Open Access
Soft Tissue Sarcomas: A 16-Year Experience of a Tertiary Referral Hospital in North Jordan
Background and Objectives: Sarcomas are rare malignant tumors of mesenchymal origin. Their low prevalence and histological heterogeneity make their diagnosis a challenging task. To the best of our knowledge, the epidemiology of soft tissue sarcomas (STSs) was not well studied in Jordan. This study thus aimed to determine STS epidemiologic trends at King Abdullah University Hospital (KAUH); a tertiary hospital that provides cancer healthcare for 70% of the population in Irbid Governorate, North Jordan. The findings of this study will provide a good reference point of the burden of STSs in Jordan and the Middle East region. Materials and Methods: All cases with confirmed STS diagnoses who attended KAUH from January 2003 until December 2018 were included in the initial analysis. Bone sarcomas, gastrointestinal stromal tumors and uterine sarcomas were not included in the study. Information collected from the pathology reports and electronic medical records was used to determine STS prevalence, incidence rate, age and gender distributions, histological types and anatomic location. Cases were reviewed by three pathologists with interest in soft tissue tumors. The findings were compared with literature. Results: In total, 157 STS cases were reported (1.9% of cancers diagnosed at KAUH during the 16-year study period). Crude annual incidence rate (IR) per 100,000 person-years ranged from 0.48 in 2015 to 1.83 in 2011 (average = 1.04). Age-standardized IR (ASR)(World WHO 2000–2025) was 1.37. Male:female ratio was 1.3:1. Median age was 39 years. Age ranged from Conclusion: STSs are rare in North Jordan. A slight increase in their incidence was identified during the study period similar to global trends. The collection of relevant data on established risk factors along with a broader scale evaluation of the epidemiology of STS in the Middle East region is recommended to better evaluate disease burden and trends.
Open AccessSoft Tissue Sarcomas: A 16-Year Experience of a Tertiary Referral Hospital in North Jordan
Background and Objectives: Sarcomas are rare malignant tumors of mesenchymal origin. Their low prevalence and histological heterogeneity make their diagnosis a challenging task. To the best of our knowledge, the epidemiology of soft tissue sarcomas (STSs) was not well studied in Jordan. This study thus aimed to determine STS epidemiologic trends at King Abdullah University Hospital (KAUH); a tertiary hospital that provides cancer healthcare for 70% of the population in Irbid Governorate, North Jordan. The findings of this study will provide a good reference point of the burden of STSs in Jordan and the Middle East region. Materials and Methods: All cases with confirmed STS diagnoses who attended KAUH from January 2003 until December 2018 were included in the initial analysis. Bone sarcomas, gastrointestinal stromal tumors and uterine sarcomas were not included in the study. Information collected from the pathology reports and electronic medical records was used to determine STS prevalence, incidence rate, age and gender distributions, histological types and anatomic location. Cases were reviewed by three pathologists with interest in soft tissue tumors. The findings were compared with literature. Results: In total, 157 STS cases were reported (1.9% of cancers diagnosed at KAUH during the 16-year study period). Crude annual incidence rate (IR) per 100,000 person-years ranged from 0.48 in 2015 to 1.83 in 2011 (average = 1.04). Age-standardized IR (ASR)(World WHO 2000–2025) was 1.37. Male:female ratio was 1.3:1. Median age was 39 years. Age ranged from Conclusion: STSs are rare in North Jordan. A slight increase in their incidence was identified during the study period similar to global trends. The collection of relevant data on established risk factors along with a broader scale evaluation of the epidemiology of STS in the Middle East region is recommended to better evaluate disease burden and trends.
- 19 February 2021
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 22, e928592-e928592-5
Brucella Septic Hip Arthritis: A Case Report
BACKGROUND:Brucellosis is a major health problem, especially in endemic countries. Although musculoskeletal system involvement is common with brucellosis, the development of septic arthritis in connection with brucellosis has been rarely reported. CASE REPORT:A 7-year-old girl presented with high-grade fever and severe right hip pain. Based on her clinical picture, laboratory tests, and radiographic images, septic arthritis was diagnosed and subsequently managed with standard septic arthritis treatment. The severity of hip pain significantly decreased after hip drainage. However, a high-grade fever persisted, raising suspicion of brucellosis, which was confirmed by serological testing. Standard treatment of brucellosis was administered and the patient responded well. CONCLUSIONS:Brucella arthritis should be considered as a differential diagnosis of septic hip, especially in endemic areas. The nonpurulent nature of the hip aspirate should raise suspicion of brucella arthritis. Early diagnosis of brucella septic arthritis is important to avoid serious complications.
- 19 February 2021
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 22, e928592-e928592-5
Brucella Septic Hip Arthritis: A Case Report
BACKGROUND:Brucellosis is a major health problem, especially in endemic countries. Although musculoskeletal system involvement is common with brucellosis, the development of septic arthritis in connection with brucellosis has been rarely reported. CASE REPORT:A 7-year-old girl presented with high-grade fever and severe right hip pain. Based on her clinical picture, laboratory tests, and radiographic images, septic arthritis was diagnosed and subsequently managed with standard septic arthritis treatment. The severity of hip pain significantly decreased after hip drainage. However, a high-grade fever persisted, raising suspicion of brucellosis, which was confirmed by serological testing. Standard treatment of brucellosis was administered and the patient responded well. CONCLUSIONS:Brucella arthritis should be considered as a differential diagnosis of septic hip, especially in endemic areas. The nonpurulent nature of the hip aspirate should raise suspicion of brucella arthritis. Early diagnosis of brucella septic arthritis is important to avoid serious complications.
- Open Access
- 29 December 2016
- Published by Springer Nature in Scoliosis and Spinal Disorders
- Vol. 11 (1) , 47
Comparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma
This was a prospective study to evaluate the effect of multilevel vertebral augmentation in addition to conventional therapy in multiple myeloma patients. We treated 27 patients, whom were recently diagnosed to have multiple myeloma by two ways of treatment. Thirteen patients (group I) were treated with conventional therapy and 14 patients (group II) with adding vertebroplasty and kyphoplasty. Patients were evaluated pre-treatment and at half, one, two and 3-years post-treatment by using Oswestry Disability Index (ODI), the Stanford Score (SS) and the Spinal Instability Neoplastic Score (SINS). Mean values of ODI, SS and SINS were 31.9 (63.8%), 4.3 and 13.8 for group I and 33.2 (66.4%), 4.6 and 12.8 for group II before starting treatment. Group II showed improvement better than group I at all follow-up intervals with best results at first 6 months. P-values at the end of the study were ODI = 0.047, SS = 0.180 and SINS = 0.002. Mortality rates were equal of both groups (four patients of each group). Adding vertebral augmentation to conventional therapy improves multiple myeloma patients’ quality of life, but didn’t affect the mortality rate.
- 29 December 2016
- Published by Springer Nature in Scoliosis and Spinal Disorders
- Vol. 11 (1) , 47
Open AccessComparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma
This was a prospective study to evaluate the effect of multilevel vertebral augmentation in addition to conventional therapy in multiple myeloma patients. We treated 27 patients, whom were recently diagnosed to have multiple myeloma by two ways of treatment. Thirteen patients (group I) were treated with conventional therapy and 14 patients (group II) with adding vertebroplasty and kyphoplasty. Patients were evaluated pre-treatment and at half, one, two and 3-years post-treatment by using Oswestry Disability Index (ODI), the Stanford Score (SS) and the Spinal Instability Neoplastic Score (SINS). Mean values of ODI, SS and SINS were 31.9 (63.8%), 4.3 and 13.8 for group I and 33.2 (66.4%), 4.6 and 12.8 for group II before starting treatment. Group II showed improvement better than group I at all follow-up intervals with best results at first 6 months. P-values at the end of the study were ODI = 0.047, SS = 0.180 and SINS = 0.002. Mortality rates were equal of both groups (four patients of each group). Adding vertebral augmentation to conventional therapy improves multiple myeloma patients’ quality of life, but didn’t affect the mortality rate.